Nephroprotection 2025: "4 Pillars" & EASi-KIDNEY Dr Doreen Zhu Dr Parminder Judge Andreas Kronbichler markusathome marcus_saemann NDT Deutsche Gesellschaft für Nephrologie (DGfN) e.V. Hans-Joachim Anders youtu.be/cpAel7yCW6I?si… via YouTube

Anti-slit diaphragm antibodies in autoimmune podocytopathy: •Anti-nephrin → frequent in kids •Anti-podocin → in kids & adults •Anti-Kirrel1 → more rare •Some patients have multiple autoantibodies. journals.lww.com/jasn/citation/…

Heute, am 5.Februar, ist es soweit: Ich darf „Marseille 1940“ in französischer Übersetzung in Marseille vorstellen! Zusammen mit Olivier Mannoni,dem großartigen Übersetzer. Das hätte ich mir nicht träumen lassen. Dank an das Goethe-Institut, die Böll-Stiftung, den Verlag Grasset.

There's no such thing as hypertensive nephropathy? A thoughtful viewpoint paper by Rajiv Agarwal MD, MS NDT Hans-Joachim Anders

The great Claudio Arrau was born on 6 February 1903. Over the last couple of years, his name has come up over and over again in your recommendations. If you could preserve one - and only one - Arrau recording, which would it be?

Among patients with IgA nephropathy, treatment with iptacopan, which inhibits the alternative complement pathway, resulted in a significant reduction in proteinuria as compared with placebo. Full APPLAUSE-IgAN trial results and Research Summary: nej.md/3UmrOkh

Obinutuzumab holds significant potential as a novel first-line therapeutic option for various immune-mediated glomerular diseases: ▫️Lupus nephritis ▫️Membranous nephropathy ▫️ANCA associated vasculitides ▫️Primary podocytopathies 🔗 doi.org/10.1093/ndt/gf…

Red Blood Cell Casts on Kidney Biopsy are associated with BETTER prognosis of IgA Nephropathy - as they indicate earlier stages of IgANP ? academic.oup.com/ndt/article-ab… NDT Hans-Joachim Anders Andreas Kronbichler Jonathan Barratt

Fourth Pillar: Semaglutide Brendon Neuen Valerie Luyckx marcus_saemann Katherine Tuttle Roser Torra FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression jamanetwork.com/journals/jama/…

Few (if any) renal benefit of intensive BP lowering: Important Reminder by Dr. R Townsend. Might a < 130 SBP target (as proposed by European Society of Cardiology) be wiser that a < 120 target (as proposed by KDIGO)? @dguerrot marcus_saemann Tobias B. Huber Hans-Joachim Anders academic.oup.com/ndt/article/do…

Kidney transplant recipients receiving GLP-1 RA had a 49% lower incidence of death-censored graft loss and 31% lower mortality than those not receiving GLP-1 RA 🤯 Proud to be a co-author on this real-world retrospective cohort study of 18,106 kidney transplant recipients with

Do we need a novel CKD definition in elderly? eGFR < 60 might over-diagnose chronic kidney "disease" in octogenarians & nonagenarians Hans-Joachim Anders Roser Torra marcus_saemann Andreas Kronbichler Tobias B. Huber Juan Jesus Carrero Prof Liz B 🇬🇧🇮🇱🇺🇦🇵🇸 Daniel Coyne Thomas Stehlé Hans Pottel Pierre Delanaye

Now open access in NDT Active glomerular inflammation versus chronicity and fibrosis: The role of targeted therapies in IgA nephropathy 🧐 Dissecting active inflammatory from chronic fibrotic phenotype will play an increasing role in IgAN ▶️academic.oup.com/ndt/article/do…

In SOUL, 2596/9650 (26.9%) participants were receiving SGLT2i at baseline (largest CVOT of combined GLP-1/SGLT2 to date) The effect of oral semaglutide on cardiovascular outcomes was consistent, regardless of SGLT2i use #ACC25 ahajournals.org/doi/abs/10.116…

Look at the y-axis. This may be another trial with statistical significance but not clinical significance. Pts have established disease. And no difference in CVD or major kidney secondary composite. Is it worth the cost? I don't think so. #ACC25

In the BPROAD trial, patients with type 2 diabetes had a lower incidence of major cardiovascular outcomes with a systolic blood-pressure target of less than 120 mm Hg than with a target of less than 140 mm Hg. Full trial results and Research Summary: nej.md/4eyDckd

As GLP-1 outcome trials are analyzed for correlations between A1c reduction, weight loss, and reduction in primary outcomes, evidence mounts for contributions from non-metabolic actions of GLP-1, including reduction of inflammation. science.org/doi/10.1126/sc…

SGLT2 Inhibitors Blunt Kidney Magnesium Wasting in Acute Cisplatin-Induced Hypomagnesemia with Effects on the TAL and DCT JASN_News -- love this paper!! journals.lww.com/jasn/abstract/…

Giving furosemide 20mg for ascites

Our new webinar in 🇩🇪🇦🇹🇨🇭🇱🇮 language: SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz) WATCH NOW: youtu.be/i_YTcIQ4YQk?si… Daniel G. Fuster Gunnar Henrik Heine marcus_saemann